Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer …
Full APVO analysis →
Competitive advantage assessment
Key strengths
Strong Interest Coverage & Conservative LeverageDebt serviceability is strong (score 0.89), with robust interest coverage.
Scale Supporting ProfitabilityProfitability at scale is strong (score 0.71), demonstrating competitive advantages.
Key risks
ROIC Below WACC or PeersROIC at 20.8th percentile suggests inefficient capital deployment.
Aptevo Therapeutics Inc. ranks #305 of 713
scored companies in Biotechnology by moat score — the top 43%.
The widest moat in the group is Royalty Pharma plc (RPRX)
at 85/100.
Moat scores for companies ranked near APVO in Biotechnology
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 40
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 46
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 16
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 66
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 55
· 15% of the moat score
Scale matters only when it converts into economics.
Aptevo Therapeutics Inc. (APVO) scores 45 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #305 of 713 scored companies in Biotechnology, the top 43%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (66/100) and its weakest is Capital Efficiency (16/100).
How does Aptevo Therapeutics Inc. compare with other Biotechnology companies?
Aptevo Therapeutics Inc. ranks #305 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are EyePoint Pharmaceuticals, Inc. (EYPT) at 45 just above it and Orchestra BioMed Holdings, Inc. (OBIO) at 45 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.
Why is Aptevo Therapeutics Inc. scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Aptevo Therapeutics Inc.?
The Corporate Default template measures 6 defenses, and APVO scores: Pricing Power (47), Cost Advantage (40), Customer Stickiness (46), Capital Efficiency (16), Resilience (66), Scale & Market Position (55). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.